KH617: A Treatment for Glioblastoma

Among malignant tumors, central nervous system tumors lead to a number of deaths closest to that of patients with new-onset diseases.

Glioblastoma is the most common and aggressive primary brain tumor, that accounts for 50% of central nervous system tumors (WHO Grade IV). Glioblastoma patients have a quite poor clinical prognosis, while the existing therapeutic drugs and medical devices are not able to meet clinical needs.

With an efficacy that is significantly superior to currently available treatments, KH617 produces a significant reduction in tumor growth rate and prolongs the overall survival in animal models.

*This is in clinical trials